Advanced Search Results For "DEATH receptors"
Your filters
Tetrandrine synergizes with MAPK inhibitors in treating KRAS-mutant pancreatic ductal adenocarcinoma via collaboratively modulating the TRAIL-death receptor axis.
Publication Type: Academic Journal
Source(s): Pharmacological research [Pharmacol Res] 2023 Nov; Vol. 197, pp. 106955. Date of Electronic Publication: 2023 Oct 14.
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal malignancies lacking effective therapies. KRAS mutations that occur in over 90% of PDAC are major oncogenic drivers of PDAC. The MAPK signaling pathway plays a central rol...
Synthesis and Evaluation of 177 Lu-DOTA-PD-L1-i and 225 Ac-HEHA-PD-L1-i as Potential Radiopharmaceuticals for Tumor Microenvironment-Targeted Radiotherapy.
Publication Type: Academic Journal
Source(s): International Journal of Molecular Sciences. Aug2023, Vol. 24 Issue 15, p12382. 19p.
Abstract: Current cancer therapies focus on reducing immunosuppression and remodeling the tumor microenvironment to inhibit metastasis, cancer progression, and therapeutic resistance. Programmed death receptor 1 (PD-1) is expressed on immune T cells and is one o...
Shikonin derivatives cause apoptosis and cell cycle arrest in human chondrosarcoma cells via death receptors and MAPK regulation.
Publication Type: Academic Journal
Source(s): BMC cancer [BMC Cancer] 2022 Jul 12; Vol. 22 (1), pp. 758. Date of Electronic Publication: 2022 Jul 12.
Abstract: Background: Although chondrosarcoma is the second most common primary malignant bone tumor, treatment options are limited due to its extensive resistance to a chemo- and radiation therapy. Since shikonin has shown potent anticancer activity in various ...
TRAIL promotes the polarization of human macrophages toward a proinflammatory M1 phenotype and is associated with increased survival in cancer patients with high tumor macrophage content.
Publication Type: Academic Journal
Source(s): Frontiers in immunology [Front Immunol] 2023 Sep 21; Vol. 14, pp. 1209249. Date of Electronic Publication: 2023 Sep 21 (Print Publication: 2023).
Abstract: Background: TNF-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily that can either induce cell death or activate survival pathways after binding to death receptors (DRs) DR4 or DR5. TRAIL is investigated as a therapeutic agent...
Various Forms of Programmed Cell Death Are Concurrently Activated in the Population of Retinal Ganglion Cells after Ischemia and Reperfusion.
Publication Type: Academic Journal
Source(s): International journal of molecular sciences [Int J Mol Sci] 2023 Jun 08; Vol. 24 (12). Date of Electronic Publication: 2023 Jun 08.
Abstract: Retinal ischemia-reperfusion (IR)-which ultimately results in retinal ganglion cell (RGC) death-is a common cause of visual impairment and blindness worldwide. IR results in various types of programmed cell death (PCD), which are of particular importan...
ZBP1-Mediated Necroptosis: Mechanisms and Therapeutic Implications.
Publication Type: Academic Journal
Source(s): Molecules. Jan2023, Vol. 28 Issue 1, p52. 20p.
Abstract: Cell death is a fundamental pathophysiological process in human disease. The discovery of necroptosis, a form of regulated necrosis that is induced by the activation of death receptors and formation of necrosome, represents a major breakthrough in the ...
Exploring the Complex Link between Autophagy, Regulated Cell Death, and Cell Fate Pathways in Cancer Pathogenesis and Therapy.
Publication Type: Academic Journal
Source(s): Cells (2073-4409). Feb2023, Vol. 12 Issue 3, p498. 5p.
Abstract: The authors provide evidence that simvastatin (Simva) enhances temozolomide (TMZ)-induced cell death in GBM cells through UPR-mediated autophagy flux in U251 (p53 mutant) and U87 (p53 wild type) GBM cells. There are three distinct forms of autophagy, i...
DR5 Up-Regulation Induced by Dichloroacetate Sensitizes Tumor Cells to Lipid Nanoparticles Decorated with TRAIL.
Publication Type: Academic Journal
Source(s): Journal of Clinical Medicine. Jan2023, Vol. 12 Issue 2, p608. 15p.
Abstract: Cancer resistance to treatments is a challenge that researchers constantly seek to overcome. For instance, TNF-related apoptosis-inducing ligand (TRAIL) is a potential good prospect as an anti-cancer therapy, as it attacks tumor cells but not normal ce...
Thymus hirtus sp. algeriensis Boiss. and Reut. volatile oil enhances TRAIL/Apo2L induced apoptosis and inhibits colon carcinogenesis through upregulation of death receptor pathway.
Publication Type: Academic Journal
Source(s): Aging [Aging (Albany NY)] 2021 Sep 20; Vol. 13 (18), pp. 21975-21990. Date of Electronic Publication: 2021 Sep 20.
Abstract: Background: The aim of the study is to determine the anticancer activity of Thymus algeriensis (TS) and its underlying mechanisms using in vitro and in animal models.Methods: HCT116 cells were treated with TS essential oil alone or with TRAIL, and then...
Recent Advances in the Development of Nanodelivery Systems Targeting the TRAIL Death Receptor Pathway.
Publication Type: Academic Journal
Source(s): Pharmaceutics. Feb2023, Vol. 15 Issue 2, p515. 37p.
Abstract: The TRAIL (TNF-related apoptosis-inducing ligand) apoptotic pathway is extensively exploited in the development of targeted antitumor therapy due to TRAIL specificity towards its cognate receptors, namely death receptors DR4 and DR5. Although therapies...